OBJECTIVES

LUCID is a pan-European cross-sectional retrospective study conducted on a sample of gastroenterologists to provide data on patients with Ulcerative Colitis (UC). This study aims to describe treatment pattern with biologics across countries, including time on treatment, and quality of life impact on UC patients.

METHODS

Descriptive analysis of the LUCID sample (n=2,966), including patients who are candidates for biologics (n=1,037, 35%) of whom n=652 (22% of the total sample) have used at least one biologic. Categorical variables were described by frequencies and percentages, continuous variables by means and standard deviation (SD).

RESULTS :

Of the 2,966 UC patients in the LUCID study, 1,638 were male (55%), mean age was 47 (SD 15), with an average of 6.4 (SD 6) years since diagnosis.

Despite some variation across countries, infliximab was generally the most prescribed biologic (n=329 of 652, 50%) followed by adalimumab (n=243, 37%) and vedolizumab (n=64, 10%). 610 (94%) patients received only one biologic, while only 42 (6%) of patients were treated with two or more biologics.

Of the patients on biologics (n=652), time from diagnosis to first biologic prescription was on average 57 months (SD 67). Mean time on treatment across all biologics and treatment lines was 14 months (SD 20). Mean time on first biologic was longer for anti-TNFs compared to other biologics. For patients with more than one biologic, time on first biologic was 16 months (SD 18) and for 2nd line was <6 months (SD 4).

Longer time on biologic treatment was associated with better functional outcomes, as measured by IBD-DI.

CONCLUSIONS

In this cohort of patients with UC, biologic uptake was 22%, with an average of almost five years to first prescription. Longer time on treatment seems to be associated with better functional outcomes.